top of page

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)

HHS-NIH11

Status:

Active

March 28, 2022

Posted:

Deadline: 

February 14, 2025

Funding

Program:

Award Floor:

Ceiling:

Match Required?

No

Eligibility

All

States:

Entity Types:

Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

Contact

Email:

Phone:

Source Type:

Federal

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and stimulant use disorders (StUD). Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics; and (2) medical therapeutic and diagnostic devices, including software as a medical device. This FOA strives to contribute to the effort against national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis.

Tired of searching for grants? Consider a Scouting Report.

bottom of page